The ROE as of November 2024 (TTM) for I-Mab (IMAB) is -25.75%

According to I-Mab’s latest financial reports and current stock price. The company's current ROE is -25.75%. This represents a change of 246.72% compared to the average of -7.43% of the last 4 quarters.

I-Mab (IMAB) Historical ROE (quarterly & annually)

How has IMAB ROE performed in the past?

The mean historical ROE of I-Mab over the last ten years is 0.51%. The current -25.75% ROE has changed -5195.05% with respect to the historical average. Over the past ten years (40 quarters), IMAB's ROE was at its highest in in the June 2019 quarter at 29.54%. The ROE was at its lowest in in the March 2019 quarter at -29.27%.

I-Mab (IMAB) ROE by Quarter and Year

Discovering the peaks and valleys of I-Mab ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

I-Mab (IMAB) Average ROE

How has IMAB ROE performed in the past?

The current ROE of I-Mab (IMAB) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

I-Mab (IMAB) ROE vs. Peers

How is IMAB’s ROE compared to its peers?

I-Mab’s ROE is greater than BeiGene, Ltd. (-14.93%), less than Krystal Biotech, Inc. (13.36%), greater than Immunovant, Inc. (-52.07%), greater than Mirati Therapeutics, Inc. (-81.10%), less than Foghorn Therapeutics Inc. (140.34%), greater than Shattuck Labs, Inc. (-68.65%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Kymera Therapeutics, Inc. (-24.96%), greater than Nurix Therapeutics, Inc. (-63.39%), greater than Lyell Immunopharma, Inc. (-33.35%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than Revolution Medicines, Inc. (-34.57%), greater than Gracell Biotechnologies Inc. (-37.20%), greater than Design Therapeutics, Inc. (-18.48%), greater than Erasca, Inc. (-131.94%), less than Ascendis Pharma A/S (251.76%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), greater than Akero Therapeutics, Inc. (-29.56%), greater than Blueprint Medicines Corporation (-47.66%),

Build a custom stock screener for I-Mab (IMAB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like I-Mab using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

I-Mab (IMAB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like I-Mab or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.